Meridian Bioscience (NASDAQ: VIVO) reported Q3 EPS of $0.21, $0.01 worse than the analyst estimate of $0.22. Revenue for the quarter came in at $50.7 million versus the consensus estimate of $52.85 million.

• updated its fiscal 2016 guidance of per share diluted earnings between $0.86 and $0.90 on a non-GAAP basis on net revenues of $195 million to $200 million, including the Magellan Diagnostics, Inc. acquisition. (consensus 88c on revenue of $203.3 million)

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.